First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated
